Exact Sciences Corp. announced that more than two million breast‑cancer patients worldwide have used its Oncotype DX Breast Recurrence Score® test to guide treatment decisions, marking a new milestone in the company’s precision‑oncology portfolio.
The Oncotype DX assay evaluates the expression of 21 genes in early‑stage, hormone‑receptor positive, HER2‑negative breast cancer to predict the likelihood of recurrence and the benefit of chemotherapy. By identifying patients who are unlikely to benefit from additional chemotherapy, the test has helped clinicians and patients avoid overtreatment and its associated side‑effects.
The milestone underscores the test’s growing adoption and its role as a standard of care in oncology. It reflects the company’s successful commercialization strategy, the integration of the test into clinical workflows worldwide, and the continued confidence of oncologists in its clinical validity. The expanding patient base also signals a solid revenue foundation for Exact Sciences’ diagnostic business, supporting future growth and potential expansion into new indications.
While Exact Sciences has not disclosed specific financial figures tied to the milestone, the continued increase in test usage is expected to drive incremental revenue and reinforce the company’s market leadership in genomic diagnostics. The company’s focus on expanding access and integrating its platform into broader oncology care pathways positions it to capture additional market share as precision‑oncology adoption accelerates globally.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.